Additionally, survival analysis showed that patients with BCAM low expression concomitant with BAP1 mutation had a worse prognosis, reconfirming the adverse impact of BAP1 mutation among ccRCC. The gene discussed is BCAM; the disease is nonpapillary renal cell carcinoma.